Research & Development
Ipsen’s commitment in research & development is our bold promise to patients, to launch at least one new drug or meaningful new indication every year. We will secure our future by building a pipeline of innovative medicines, establishing our leadership position in key therapeutic areas, sustainable lifecycle management and, most importantly, with great people throughout our R&D organization.
Our research & development strategy is guided by the principle of service to patients, to deliver therapeutic solutions for unmet medical needs, in oncology, neurosciences and rare diseases. We are recognized for our unique expertise in neurotoxin biology.
Ipsen R&D has a valuable pipeline encompassing both lifecycle management of our well-established products, and the development of innovative new molecules, including small molecules, neurotoxins and theranostics.
Three therapeutic areas
Ipsen focuses on three therapeutic areas, oncology, neurosciences and rare diseases, developing innovative and differentiated therapies in areas of high unmet medical need. Our specialized portfolio of products, combined with our strong clinical and regulatory skillset, will allow us to continue to expand indications across existing therapies and bring new treatments for patients.
Internationally renowned R&D centers
With an open innovation model in mind, we have placed our three R&D centres at the heart of three internationally reputed scientific hubs: Paris-Saclay in France, Oxford in the United Kingdom and Cambridge in the United States, in contact with leading academic research centers, medical centers and technology companies.
A Development Powerhouse
Our biotech mindset, combined with the scale and advantages of a global pharmaceutical company, has established us as a development powerhouse in our core focus areas. We have therapeutically-aligned teams, global expertise in regulatory affairs, patient safety and medical affairs, and a proven ability to bring new, life changing therapies successfully through clinical development.
We make sure we access the best information and opportunities provided through external networks, and maximize the potential for in-licensing novel and life-changing treatments. The partnerships that we develop with leading academic institutes, biotechs and medical centers allow us to test the relevance of our research concepts.